April 2, 2019
Generic major Nichi-Iko Pharmaceutical took over Torii Pharmaceutical’s mainstay protease inhibitor Futhan (nafamostat) on April 1 - a year after the drug faced a whopping 43.4% price cut under a revamped off-patent re-pricing scheme, which apparently triggered the deal. Nichi-Iko...read more